76 results on '"Karayan-Tapon L"'
Search Results
2. 159P SiMosein, a real-life prospective evaluation of EndoPredict use in early ER-positive, HER2-negative breast cancers
- Author
-
Lehmann-Che, J., primary, Wong, J., additional, Lacroix, L., additional, Lacroix-Triki, M., additional, Arnould, L., additional, Lamy, P.J., additional, Quillien, V., additional, Godey, F., additional, Soubeyran, I., additional, MacGrogan, G., additional, Haudebourg, J., additional, Dupé, M., additional, Heymann, M-F., additional, Raoux, D., additional, Manz, S., additional, Tallet, A., additional, Padilla, N., additional, Dainese, L., additional, Karayan-Tapon, L., additional, and Penault-Llorca, F., additional
- Published
- 2021
- Full Text
- View/download PDF
3. 1472P Circulating tumor DNA in unresectable pancreatic cancer is a strong predictor of response to first-line therapy: The KRASCIPANC study
- Author
-
Evrard, C., primary, Ingrand, P., additional, Tachon, G., additional, Flores, N., additional, Rochelle, T., additional, Martel, M., additional, Randrian, V., additional, Ferru, A., additional, Haineaux, P-A., additional, Isambert, N., additional, Karayan Tapon, L., additional, and Tougeron, D., additional
- Published
- 2021
- Full Text
- View/download PDF
4. Effect of low-frequency KRAS mutations on the response to anti-EGFR therapy in metastatic colorectal cancer
- Author
-
Tougeron, D., Lecomte, T., Pagès, J. C., Villalva, C., Collin, C., Ferru, A., Tourani, J. M., Silvain, C., Levillain, P., and Karayan-Tapon, L.
- Published
- 2013
- Full Text
- View/download PDF
5. Dual MGMT inactivation by promoter hypermethylation and loss of chromosome 10q as relevant prognostic marker in glioblastoma
- Author
-
Tachon, G., primary, Richard, S., additional, Milin, S., additional, Wager, M., additional, and Karayan-Tapon, L., additional
- Published
- 2019
- Full Text
- View/download PDF
6. 16P - Dual MGMT inactivation by promoter hypermethylation and loss of chromosome 10q as relevant prognostic marker in glioblastoma
- Author
-
Tachon, G., Richard, S., Milin, S., Wager, M., and Karayan-Tapon, L.
- Published
- 2019
- Full Text
- View/download PDF
7. Clinical characteristics of colorectal cancer patients with brain metastases: An "Association des Gastro-Éntérologues Oncologues" (AGEO) multicenter study
- Author
-
Roussille, P., primary, Dior, M., additional, Locher, C., additional, Mabro, M., additional, Artru, P., additional, Tachon, G., additional, Frouin, É, additional, Berger, A., additional, Wager, M., additional, Goujon, J.-M., additional, Karayan-Tapon, L., additional, and Tougeron, D., additional
- Published
- 2016
- Full Text
- View/download PDF
8. A mesenchymal glioma stem cell profile is related to clinical outcome
- Author
-
Balbous, A, primary, Cortes, U, additional, Guilloteau, K, additional, Villalva, C, additional, Flamant, S, additional, Gaillard, A, additional, Milin, S, additional, Wager, M, additional, Sorel, N, additional, Guilhot, J, additional, Bennaceur-Griscelli, A, additional, Turhan, A, additional, Chomel, J-C, additional, and Karayan-Tapon, L, additional
- Published
- 2014
- Full Text
- View/download PDF
9. 587P - Clinical characteristics of colorectal cancer patients with brain metastases: An "Association des Gastro-Éntérologues Oncologues" (AGEO) multicenter study
- Author
-
Roussille, P., Dior, M., Locher, C., Mabro, M., Artru, P., Tachon, G., Frouin, É, Berger, A., Wager, M., Goujon, J.-M., Karayan-Tapon, L., and Tougeron, D.
- Published
- 2016
- Full Text
- View/download PDF
10. Semaphorin, neuropilin and VEGF expression in glial tumours: SEMA3G, a prognostic marker?
- Author
-
Karayan-Tapon, L, primary, Wager, M, additional, Guilhot, J, additional, Levillain, P, additional, Marquant, C, additional, Clarhaut, J, additional, Potiron, V, additional, and Roche, J, additional
- Published
- 2008
- Full Text
- View/download PDF
11. Prognostic molecular markers with no impact on decision-making: the paradox of gliomas based on a prospective study
- Author
-
Wager, M, primary, Menei, P, additional, Guilhot, J, additional, Levillain, P, additional, Michalak, S, additional, Bataille, B, additional, Blanc, J-L, additional, Lapierre, F, additional, Rigoard, P, additional, Milin, S, additional, Duthe, F, additional, Bonneau, D, additional, Larsen, C-J, additional, and Karayan-Tapon, L, additional
- Published
- 2008
- Full Text
- View/download PDF
12. The status of CDKN2A alpha (p16INK4A) and beta (p14ARF) transcripts in thyroid tumour progression
- Author
-
Ferru, A, primary, Fromont, G, additional, Gibelin, H, additional, Guilhot, J, additional, Savagner, F, additional, Tourani, J M, additional, Kraimps, J L, additional, Larsen, C J, additional, and Karayan-Tapon, L, additional
- Published
- 2006
- Full Text
- View/download PDF
13. Prognostic value of increase in transcript levels of Tp73 ΔEx2-3 isoforms in low-grade glioma patients
- Author
-
Wager, M, primary, Guilhot, J, additional, Blanc, J-L, additional, Ferrand, S, additional, Milin, S, additional, Bataille, B, additional, Lapierre, F, additional, Denis, S, additional, Chantereau, T, additional, Larsen, C-J, additional, and Karayan-Tapon, L, additional
- Published
- 2006
- Full Text
- View/download PDF
14. Prognostic value of increase in transcript levels of Tp73 DeltaEx2-3 isoforms in low-grade glioma patients.
- Author
-
Wager, M., Guilhot, J., Blanc, J.-L., Ferrand, S., Milin, S., Bataille, B., Lapierre, F., Denis, S., Chantereau, T., Larsen, C.-J., and Karayan-Tapon, L.
- Subjects
TUMORS ,POLYMERASE chain reaction ,GLIOMAS ,GENETIC transcription ,PEOPLE with epilepsy ,NEUROGLIA ,PROGNOSIS ,RNA metabolism ,PROTEINS ,RESEARCH ,NUCLEAR proteins ,MULTIVARIATE analysis ,RESEARCH methodology ,RNA ,EVALUATION research ,COMPARATIVE studies ,DNA-binding proteins ,KAPLAN-Meier estimator ,GENES - Abstract
Glial tumours are a devastating, poorly understood condition carrying a gloomy prognosis for which clinicians sorely lack reliable predictive parameters facilitating a sound treatment strategy. Tp73, a p53 family member, expresses two main classes of isoforms--transactivatory activity (TA)p73 and DeltaTAp73--exhibiting tumour suppressor gene and oncogene properties, respectively. The authors examined their expression status in high- and low-grade adult gliomas. Isoform-specific real-time reverse transcription-polymerase chain reaction was used for the analysis of Tp73 isoform transcript expression in a series of 51 adult patients harbouring glial tumours, in order to compare tumour grades with each other, and with non-tumoural samples obtained from epileptic patients as well. Our data demonstrate increase of TAp73 and DeltaTAp73 transcript levels at onset and early stage of the disease. We also show that DeltaEx2-3 isoform expression in low-grade tumours anticipates clinical and imaging progression to higher grades, and correlates to the patients' survival. Expression levels of P1 promoter generated Tp73 isoforms--and particularly DeltaEx2-3--indeed allow for prediction of the clinical progression of low-grade gliomas in adults. Our data are the first such molecular biology report regarding low-grade tumours and as such should be of help for sound decision-making. [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
15. An ANOCEF genomic and transcriptomic microarray study of the response to radiotherapy or to alkylating first-line chemotherapy in glioblastoma patients
- Author
-
Ducray François, de Reyniès Aurélien, Chinot Olivier, Idbaih Ahmed, Figarella-Branger Dominique, Colin Carole, Karayan-Tapon Lucie, Chneiweiss Hervé, Wager Michel, Vallette François, Marie Yannick, Rickman David, Thomas Emilie, Delattre Jean-Yves, Honnorat Jérôme, Sanson Marc, and Berger François
- Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background The molecular characteristics associated with the response to treatment in glioblastomas (GBMs) remain largely unknown. We performed a retrospective study to assess the genomic characteristics associated with the response of GBMs to either first-line chemotherapy or radiation therapy. The gene expression (n = 56) and genomic profiles (n = 67) of responders and non-responders to first-line chemotherapy or radiation therapy alone were compared on Affymetrix Plus 2 gene expression arrays and BAC CGH arrays. Results According to Verhaak et al.'s classification system, mesenchymal GBMs were more likely to respond to radiotherapy than to first-line chemotherapy, whereas classical GBMs were more likely to respond to first-line chemotherapy than to radiotherapy. In patients treated with radiation therapy alone, the response was associated with differential expression of microenvironment-associated genes; the expression of hypoxia-related genes was associated with short-term progression-free survival (< 5 months), whereas the expression of immune genes was associated with prolonged progression-free survival (> 10 months). Consistently, infiltration of the tumor by both CD3 and CD68 cells was significantly more frequent in responders to radiotherapy than in non-responders. In patients treated with first-line chemotherapy, the expression of stem-cell genes was associated with resistance to chemotherapy, and there was a significant association between response to treatment and p16 locus deletions. Consistently, in an independent data set of patients treated with either radiotherapy alone or with both radiotherapy and adjuvant chemotherapy, we found that patients with the p16 deletion benefited from adjuvant chemotherapy regardless of their MGMT promoter methylation status, whereas in patients without the p16 deletion, this benefit was only observed in patients with a methylated MGMT promoter. Conclusion Differential expression of microenvironment genes and p16 locus deletion are associated with responses to radiation therapy and to first-line chemotherapy, respectively, in GBM. Recently identified transcriptomic subgroups of GBMs seem to respond differently to radiotherapy and to first-line chemotherapy.
- Published
- 2010
- Full Text
- View/download PDF
16. VC-resist glioblastoma cell state: vessel co-option as a key driver of chemoradiation resistance.
- Author
-
Pichol-Thievend C, Anezo O, Pettiwala AM, Bourmeau G, Montagne R, Lyne AM, Guichet PO, Deshors P, Ballestín A, Blanchard B, Reveilles J, Ravi VM, Joseph K, Heiland DH, Julien B, Leboucher S, Besse L, Legoix P, Dingli F, Liva S, Loew D, Giani E, Ribecco V, Furumaya C, Marcos-Kovandzic L, Masliantsev K, Daubon T, Wang L, Diaz AA, Schnell O, Beck J, Servant N, Karayan-Tapon L, Cavalli FMG, and Seano G
- Subjects
- Humans, Animals, Cell Line, Tumor, Mice, Chemoradiotherapy methods, Drug Resistance, Neoplasm, Gene Expression Regulation, Neoplastic, Radiation Tolerance, YAP-Signaling Proteins metabolism, Brain metabolism, Brain pathology, Proteomics, Glioblastoma metabolism, Glioblastoma pathology, Glioblastoma drug therapy, Glioblastoma genetics, Brain Neoplasms metabolism, Brain Neoplasms pathology, Brain Neoplasms drug therapy, Brain Neoplasms genetics
- Abstract
Glioblastoma (GBM) is a highly lethal type of cancer. GBM recurrence following chemoradiation is typically attributed to the regrowth of invasive and resistant cells. Therefore, there is a pressing need to gain a deeper understanding of the mechanisms underlying GBM resistance to chemoradiation and its ability to infiltrate. Using a combination of transcriptomic, proteomic, and phosphoproteomic analyses, longitudinal imaging, organotypic cultures, functional assays, animal studies, and clinical data analyses, we demonstrate that chemoradiation and brain vasculature induce cell transition to a functional state named VC-Resist (vessel co-opting and resistant cell state). This cell state is midway along the transcriptomic axis between proneural and mesenchymal GBM cells and is closer to the AC/MES1-like state. VC-Resist GBM cells are highly vessel co-opting, allowing significant infiltration into the surrounding brain tissue and homing to the perivascular niche, which in turn induces even more VC-Resist transition. The molecular and functional characteristics of this FGFR1-YAP1-dependent GBM cell state, including resistance to DNA damage, enrichment in the G2M phase, and induction of senescence/stemness pathways, contribute to its enhanced resistance to chemoradiation. These findings demonstrate how vessel co-option, perivascular niche, and GBM cell plasticity jointly drive resistance to therapy during GBM recurrence., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
17. The Vitamin K-Dependent Anticoagulant Factor, Protein S, Regulates Vascular Permeability.
- Author
-
Joussaume A, Kanthou C, Pardo OE, Karayan-Tapon L, Benzakour O, and Dkhissi F
- Abstract
Protein S (PROS1) is a vitamin K-dependent anticoagulant factor, which also acts as an agonist for the TYRO3, AXL, and MERTK (TAM) tyrosine kinase receptors. PROS1 is produced by the endothelium which also expresses TAM receptors, but little is known about its effects on vascular function and permeability. Transwell permeability assays as well as Western blotting and immunostaining analysis were used to monitor the possible effects of PROS1 on both endothelial cell permeability and on the phosphorylation state of specific signaling proteins. We show that human PROS1, at its circulating concentrations, substantially increases both the basal and VEGFA-induced permeability of endothelial cell (EC) monolayers. PROS1 induces p38 MAPK (Mitogen Activated Protein Kinase), Rho/ROCK (Rho-associated protein kinase) pathway activation, and actin filament remodeling, as well as substantial changes in Vascular Endothelial Cadherin (VEC) distribution and its phosphorylation on Ser
665 and Tyr685 . It also mediates c-Src and PAK-1 (p21-activated kinase 1) phosphorylation on Tyr416 and Ser144 , respectively. Exposure of EC to human PROS1 induces VEC internalization as well as its cleavage into a released fragment of 100 kDa and an intracellular fragment of 35 kDa. Using anti-TAM neutralizing antibodies, we demonstrate that PROS1-induced VEC and c-Src phosphorylation are mediated by both the MERTK and TYRO3 receptors but do not involve the AXL receptor. MERTK and TYRO3 receptors are also responsible for mediating PROS1-induced MLC (Myosin Light Chain) phosphorylation on a site targeted by the Rho/ROCK pathway. Our report provides evidence for the activation of the c-Src/VEC and Rho/ROCK/MLC pathways by PROS1 for the first time and points to a new role for PROS1 as an endogenous vascular permeabilizing factor., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.- Published
- 2024
- Full Text
- View/download PDF
18. Yes-Associated Protein Nuclear Translocation Is Regulated by Epidermal Growth Factor Receptor Activation Through Phosphatase and Tensin Homolog/AKT Axis in Glioblastomas.
- Author
-
Masliantsev K, Mordrel M, Banor T, Desette A, Godet J, Milin S, Wager M, Karayan-Tapon L, and Guichet PO
- Subjects
- Adult, Humans, YAP-Signaling Proteins, Proto-Oncogene Proteins c-akt metabolism, Tensins metabolism, Transcription Factors genetics, Transcription Factors metabolism, ErbB Receptors metabolism, Glioblastoma genetics
- Abstract
Gliomas are the most common and lethal primary brain tumors in adults. Glioblastomas, the most frequent and aggressive form of gliomas, represent a therapeutic challenge as no curative treatment exists to date, and the prognosis remains extremely poor. Recently, the transcriptional cofactors Yes-associated protein (YAP) and transcriptional co-activator with PDZ-binding motif (TAZ) belonging to the Hippo pathway have emerged as a major determinant of malignancy in solid tumors, including gliomas. However, the mechanisms involved in its regulation, particularly in brain tumors, remain ill-defined. In glioblastomas, EGFR represents one of the most altered oncogenes affected by chromosomal rearrangements, mutations, amplifications, and overexpression. In this study, we investigated the potential link between epidermal growth factor receptor (EGFR) and the transcriptional cofactors YAP and TAZ by in situ and in vitro approaches. We first studied their activation on tissue microarray, including 137 patients from different glioma molecular subtypes. We observed that YAP and TAZ nuclear location was highly associated with isocitrate dehydrogenase 1/2 (IDH1/2) wild-type glioblastomas and poor patient outcomes. Interestingly, we found an association between EGFR activation and YAP nuclear location in glioblastoma clinical samples, suggesting a link between these 2 markers contrary to its ortholog TAZ. We tested this hypothesis in patient-derived glioblastoma cultures by pharmacologic inhibition of EGFR using gefinitib. We showed an increase of S397-YAP phosphorylation associated with decreased AKT phosphorylation after EGFR inhibition in phosphatase and tensin homolog (PTEN) wild-type cultures, unlike PTEN-mutated cell lines. Finally, we used bpV(HOpic), a potent PTEN inhibitor, to mimic the effect of PTEN mutations. We found that the inhibition of PTEN was sufficient to revert back the effect induced by Gefitinib in PTEN-wild-type cultures. Altogether, to our knowledge, these results show for the first time the regulation of pS397-YAP by the EGFR-AKT axis in a PTEN-dependent manner., (Copyright © 2022 United States & Canadian Academy of Pathology. Published by Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
19. Deciphering Brain Metastasis Stem Cell Properties From Colorectal Cancer Highlights Specific Stemness Signature and Shared Molecular Features.
- Author
-
Desette A, Guichet PO, Emambux S, Masliantsev K, Cortes U, Ndiaye B, Milin S, George S, Faigner M, Tisserand J, Gaillard A, Brot S, Wager M, Tougeron D, and Karayan-Tapon L
- Subjects
- Humans, Mice, Animals, Mice, Nude, Neoplastic Stem Cells metabolism, Heterografts, Colorectal Neoplasms pathology, Brain Neoplasms genetics, Brain Neoplasms metabolism, Brain Neoplasms pathology
- Abstract
Background & Aims: Brain metastases (BMs) from colorectal cancer (CRC) are associated with significant morbidity and mortality, with chemoresistance and short overall survival. Migrating cancer stem cells with the ability to initiate BM have been described in breast and lung cancers. In this study, we describe the identification and characterization of cancer stem cells in BM from CRC., Methods: Four brain metastasis stem cell lines from patients with colorectal cancer (BM-SC-CRC1 to BM-SC-CRC4) were obtained by mechanical dissociation of patient's tumors and selection of cancer stem cells by appropriate culture conditions. BM-SC-CRCs were characterized in vitro by clonogenic and limiting-dilution assays, as well as immunofluorescence and Western blot analyses. In ovo, a chicken chorioallantoic membrane (CAM) model and in vivo, xenograft experiments using BALB/c-nude mice were realized. Finally, a whole exome and RNA sequencing analyses were performed., Results: BM-SC-CRC formed metaspheres and contained tumor-initiating cells with self-renewal properties. They expressed stem cell surface markers (CD44v6, CD44, and EpCAM) in serum-free medium and CRC markers (CK19, CK20 and CDX-2) in fetal bovine serum-enriched medium. The CAM model demonstrated their invasive and migratory capabilities. Moreover, mice intracranial xenotransplantation of BM-SC-CRCs adequately recapitulated the original patient BM phenotype. Finally, transcriptomic and genomic approaches showed a significant enrichment of invasiveness and specific stemness signatures and highlighted KMT2C as a potential candidate gene to potentially identify high-risk CRC patients., Conclusions: This original study represents the first step in CRC BM initiation and progression comprehension, and further investigation could open the way to new therapeutics avenues to improve patient prognosis., (Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
20. L1 chimeric transcripts are expressed in healthy brain and their deregulation in glioma follows that of their host locus.
- Author
-
Pinson ME, Court F, Masson A, Renaud Y, Fantini A, Bacoeur-Ouzillou O, Barriere M, Pereira B, Guichet PO, Chautard E, Karayan-Tapon L, Verrelle P, Arnaud P, and Vaurs-Barrière C
- Subjects
- Brain, Humans, Long Interspersed Nucleotide Elements genetics, Promoter Regions, Genetic genetics, Glioma genetics, Retroelements genetics
- Abstract
Besides the consequences of retrotransposition, long interspersed element 1 (L1) retrotransposons can affect the host genome through their antisense promoter. In addition to the sense promoter, the evolutionarily recent L1 retrotransposons, which are present in several thousand copies, also possess an anti-sense promoter that can produce L1 chimeric transcripts (LCT) composed of the L1 5' UTR followed by the adjacent genomic sequence. The full extent to which LCT expression occurs in a given tissue and whether disruption of the defense mechanisms that normally control L1 retrotransposons affects their expression and function in cancer cells, remain to be established. By using CLIFinder, a dedicated bioinformatics tool, we found that LCT expression was widespread in normal brain and aggressive glioma samples, and that approximately 17% of recent L1 retrotransposons, from the L1PA1 to L1PA7 subfamilies, were involved in their production. Importantly, the transcriptional activities of the L1 antisense promoters and of their host loci were coupled. Accordingly, we detected LCT-producing L1 retrotransposons mainly in transcriptionally active genes and genomic loci. Moreover, changes in the host genomic locus expression level in glioma were associated with a similar change in LCT expression level, regardless of the L1 promoter methylation status. Our findings support a model in which the host genomic locus transcriptional activity is the main driving force of LCT expression. We hypothesize that this model is more applicable when host gene and LCT are transcribed from the same strand., (© The Author(s) 2022. Published by Oxford University Press.)
- Published
- 2022
- Full Text
- View/download PDF
21. The Long Non-Coding RNA HOXA-AS2 Promotes Proliferation of Glioma Stem Cells and Modulates Their Inflammation Pathway Mainly through Post-Transcriptional Regulation.
- Author
-
Le Boiteux E, Guichet PO, Masliantsev K, Montibus B, Vaurs-Barriere C, Gonthier-Gueret C, Chautard E, Verrelle P, Karayan-Tapon L, Fogli A, Court F, and Arnaud P
- Subjects
- Cell Line, Tumor, Cell Proliferation genetics, Gene Expression Regulation, Neoplastic, Humans, Inflammation genetics, Neoplastic Stem Cells metabolism, Glioma genetics, Glioma pathology, RNA, Long Noncoding genetics, RNA, Long Noncoding metabolism
- Abstract
Glioblastomas represent approximatively half of all gliomas and are the most deadly and aggressive form. Their therapeutic resistance and tumor relapse rely on a subpopulation of cells that are called Glioma Stem Cells (GSCs). Here, we investigated the role of the long non-coding RNA HOXA-AS2 in GSC biology using descriptive and functional analyses of glioma samples classified according to their isocitrate dehydrogenase ( IDH ) gene mutation status, and of GSC lines. We found that HOXA-AS2 is overexpressed only in aggressive ( IDHwt ) glioma and GSC lines. ShRNA-based depletion of HOXA-AS2 in GSCs decreased cell proliferation and altered the expression of several hundreds of genes. Integrative analysis revealed that these expression changes were not associated with changes in DNA methylation or chromatin signatures at the promoter of the majority of genes deregulated following HOXA-AS2 silencing in GSCs, suggesting a post-transcriptional regulation. In addition, transcription factor binding motif enrichment and correlation analyses indicated that HOXA-AS2 affects, directly or indirectly, the expression of key transcription factors implicated in GCS biology, including E2F8, E2F1, STAT1, and ATF3, thus contributing to GCS aggressiveness by promoting their proliferation and modulating the inflammation pathway.
- Published
- 2022
- Full Text
- View/download PDF
22. Heterogeneity of Mismatch Repair Status and Microsatellite Instability between Primary Tumour and Metastasis and Its Implications for Immunotherapy in Colorectal Cancers.
- Author
-
Evrard C, Messina S, Sefrioui D, Frouin É, Auriault ML, Chautard R, Zaanan A, Jaffrelot M, De La Fouchardière C, Aparicio T, Coriat R, Godet J, Silvain C, Randrian V, Sabourin JC, Guimbaud R, Miquelestorena-Standley E, Lecomte T, Moulin V, Karayan-Tapon L, Tachon G, and Tougeron D
- Subjects
- DNA Mismatch Repair genetics, Humans, Immunohistochemistry, Immunotherapy, Colorectal Neoplasms drug therapy, Colorectal Neoplasms therapy, Microsatellite Instability
- Abstract
Deficient mismatch repair system (dMMR)/microsatellite instability (MSI) is found in about 5% of metastatic colorectal cancers (mCRCs) with a major therapeutic impact for immune checkpoint inhibitor (ICI) use. We conducted a multicentre study including all consecutive patients with a dMMR/MSI mCRC. MSI status was determined using the Pentaplex panel and expression of the four MMR proteins was evaluated by immunohistochemistry (IHC). The primary endpoint was the rate of discordance of dMMR/MSI status between primary tumours and paired metastases. We included 99 patients with a dMMR/MSI primary CRC and 117 paired metastases. Only four discrepancies (3.4%) with a dMMR/MSI primary CRC and a pMMR/MSS metastasis were initially identified and reviewed by expert pathologists and molecular biologists. Two cases were false discrepancies due to human or technical errors. One discordant case could not be confirmed due to the low level of tumour cells. The last case had a confirmed discrepancy with a dMMR/MSI primary CRC and a pMMR/MSS peritoneal metastasis. Our study demonstrated a high concordance rate of dMMR/MSI status between primary CRCs and their metastases. The analysis of one sample, either from the primary tumour or metastasis, with consistent dMMR and MSI status seems to be sufficient prior to treatment with ICI.
- Published
- 2022
- Full Text
- View/download PDF
23. HSP110 as a Diagnostic but Not a Prognostic Biomarker in Colorectal Cancer With Microsatellite Instability.
- Author
-
Tachon G, Chong-Si-Tsaon A, Lecomte T, Junca A, Frouin É, Miquelestorena-Standley E, Godet J, Evrard C, Randrian V, Chautard R, Auriault ML, Moulin V, Guyetant S, Fromont G, Karayan-Tapon L, and Tougeron D
- Abstract
Determination of microsatellite instability (MSI) using molecular test and deficient mismatch repair (dMMR) using immunohistochemistry (IHC) has major implications on colorectal cancer (CRC) management. The HSP110 T
17 microsatellite has been reported to be more monomorphic than the common markers used for MSI determination. Large deletion of HSP110 T17 has been associated with efficacy of adjuvant chemotherapy in dMMR/MSI CRCs. The aim of this study was to evaluate the interest of HSP110 deletion/expression as a diagnostic tool of dMMR/MSI CRCs and a predictive tool of adjuvant chemotherapy efficacy. All patients with MSI CRC classified by molecular testing were included in this multicenter prospective cohort ( n = 381). IHC of the 4 MMR proteins was carried out. HSP110 expression was carried out by IHC ( n = 343), and the size of HSP110 T17 deletion was determined by PCR (n = 327). In the 293 MSI CRCs with both tests, a strong correlation was found between the expression of HSP110 protein and the size of HSP110 T17 deletion. Only 5.8% of MSI CRCs had no HSP110 T17 deletion ( n = 19/327). HSP110 T17 deletion helped to re-classify 4 of the 9 pMMR/MSI discordance cases as pMMR/MSS cases. We did not observe any correlation between HSP110 expression or HSP110 T17 deletion size with time to recurrence in patients with stage II and III CRC, treated with or without adjuvant chemotherapy. HSP110 is neither a robust prognosis marker nor a predictor tool of adjuvant chemotherapy efficacy in dMMR/MSI CRC. However, HSP110 T17 is an interesting marker, which may be combined with the other pentaplex markers to identify discordant cases between MMR IHC and MSI., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Tachon, Chong-Si-Tsaon, Lecomte, Junca, Frouin, Miquelestorena-Standley, Godet, Evrard, Randrian, Chautard, Auriault, Moulin, Guyetant, Fromont, Karayan-Tapon and Tougeron.)- Published
- 2022
- Full Text
- View/download PDF
24. MEOX2 Transcription Factor Is Involved in Survival and Adhesion of Glioma Stem-like Cells.
- Author
-
Tachon G, Masliantsev K, Rivet P, Desette A, Milin S, Gueret E, Wager M, Karayan-Tapon L, and Guichet PO
- Abstract
The high expression of MEOX2 transcription factor is closely associated with poor overall survival in glioma. MEOX2 has recently been described as an interesting prognostic biomarker, especially for lower grade glioma. MEOX2 has never been studied in glioma stem-like cells (GSC), responsible for glioma recurrence. The aim of our study was to investigate the role of MEOX2 in GSC. Loss of function approach using siRNA was used to assess the impact of MEOX2 on GSC viability and stemness phenotype. MEOX2 was localized in the nucleus and its expression was heterogeneous between GSCs. MEOX2 expression depends on the methylation state of its promoter and is strongly associated with IDH mutations. MEOX2 is involved in cell proliferation and viability regulation through ERK/MAPK and PI3K/AKT pathways. MEOX2 loss of function correlated with GSC differentiation and acquisition of neuronal lineage characteristics. Besides, inhibition of MEOX2 is correlated with increased expression of CDH10 and decreased pFAK. In this study, we unraveled, for the first time, MEOX2 contribution to cell viability and proliferation through AKT/ERK pathway and its potential involvement in phenotype and adhesion properties of GSC.
- Published
- 2021
- Full Text
- View/download PDF
25. New Artificial Intelligence Score and Immune Infiltrates as Prognostic Factors in Colorectal Cancer With Brain Metastases.
- Author
-
Randrian V, Desette A, Emambux S, Derangere V, Roussille P, Frouin E, Godet J, Karayan-Tapon L, Ghiringhelli F, and Tougeron D
- Subjects
- Adult, Aged, Aged, 80 and over, Artificial Intelligence, B7-H1 Antigen immunology, Female, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Prognosis, T-Lymphocytes immunology, Brain Neoplasms immunology, Brain Neoplasms mortality, Brain Neoplasms pathology, Brain Neoplasms secondary, Colorectal Neoplasms immunology, Colorectal Neoplasms mortality, Colorectal Neoplasms pathology
- Abstract
Incidence of brain metastases has increased in patients with colorectal cancer (CRC) as their survival has improved. CD3 T-cells and, lately, DGMate (DiGital tuMor pArameTErs) score, have been identified as prognostic factors in locally advanced CRC. Until now, there is no data concerning the prognostic value of these markers in patients with CRC-derived brain metastases. All consecutive patients with CRC-derived brain metastases diagnosed between 2000 and 2017 were retrospectively included. Staining for CD3, CD8, PD-1, PD-L1 and DGMate analyses were performed using tissue micro-array from primary tumors and, if available, brain metastases. All in all, 83 patients were included with 80 primary tumor samples and 37 brain metastases samples available. CD3 and CD8 T-cell infiltration was higher in primary tumors compared to brain metastases. We observed a significant higher DGMate score in rectal tumors compared to colon tumors (p=0.03). We also noted a trend of higher CD3 T-cell infiltration in primary tumors when brain metastases were both supra and subtentorial compared to brain metastases that were only subtentorial or supratentorial (p=0.36 and p=0.03, respectively). No correlation was found between CD3 or CD8 infiltration or DGMate score in primary tumors or brain metastases and overall survival (OS) in the overall population. In patients with rectal tumors, a high DGMate score in brain metastases was associated with longer OS (13.4 ± 6.1 months versus 6.1 ± 1.4 months, p=0.02). High CD3 T-cell infiltration in brain metastases was associated with lower OS in patients with supratentorial brain metastases (9.8 ± 3.3 months versus 16.7 ± 5.9 months, p=0.03). PD-L1 overexpression was rare, both in primary tumors and brain metastases, but PD-L1 positive primary tumors were associated with worse OS (p=0.01). In contrast to breast and lung cancer derived brain metastases, CD3 and CD8 infiltration and DGMate score are not major prognostic factors in patients with CRC-derived brain metastases., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationship that could be construed as a potential conflict of interest., (Copyright © 2021 Randrian, Desette, Emambux, Derangere, Roussille, Frouin, Godet, Karayan-Tapon, Ghiringhelli and Tougeron.)
- Published
- 2021
- Full Text
- View/download PDF
26. Widespread overexpression from the four DNA hypermethylated HOX clusters in aggressive (IDHwt) glioma is associated with H3K27me3 depletion and alternative promoter usage.
- Author
-
Le Boiteux E, Court F, Guichet PO, Vaurs-Barrière C, Vaillant I, Chautard E, Verrelle P, Costa BM, Karayan-Tapon L, Fogli A, and Arnaud P
- Subjects
- Brain Neoplasms enzymology, Brain Neoplasms pathology, Cell Line, Tumor, Gene Expression Regulation, Neoplastic, Glioma enzymology, Glioma pathology, Humans, Isocitrate Dehydrogenase genetics, Transcription, Genetic, Brain Neoplasms genetics, DNA Methylation, Genes, Homeobox, Glioma genetics, Histones genetics, Promoter Regions, Genetic
- Abstract
In human, the 39 coding HOX genes and 18 referenced noncoding antisense transcripts are arranged in four genomic clusters named HOXA, B, C, and D. This highly conserved family belongs to the homeobox class of genes that encode transcription factors required for normal development. Therefore, HOX gene deregulation might contribute to the development of many cancer types. Here, we study HOX gene deregulation in adult glioma, a common type of primary brain tumor. We performed extensive molecular analysis of tumor samples, classified according to their isocitrate dehydrogenase (IDH1) gene mutation status, and of glioma stem cells. We found widespread expression of sense and antisense HOX transcripts only in aggressive (IDHwt) glioma samples, although the four HOX clusters displayed DNA hypermethylation. Integrative analysis of expression, DNA methylation, and histone modification signatures along the clusters revealed that HOX gene upregulation relies on canonical and alternative bivalent CpG island promoters that escape hypermethylation. H3K27me3 loss at these promoters emerges as the main cause of widespread HOX gene upregulation in IDHwt glioma cell lines and tumors. Our study provides the first comprehensive description of the epigenetic changes at HOX clusters and their contribution to the transcriptional changes observed in adult glioma. It also identified putative 'master' HOX proteins that might contribute to the tumorigenic potential of glioma stem cells., (© 2021 The Authors. Molecular Oncology published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies.)
- Published
- 2021
- Full Text
- View/download PDF
27. Hippo Signaling Pathway in Gliomas.
- Author
-
Masliantsev K, Karayan-Tapon L, and Guichet PO
- Subjects
- Animals, Brain Neoplasms pathology, Glioma pathology, Glioma therapy, Hippo Signaling Pathway, Humans, Brain Neoplasms metabolism, Glioma metabolism, Neoplasm Proteins metabolism, Protein Serine-Threonine Kinases metabolism, Signal Transduction
- Abstract
The Hippo signaling pathway is a highly conserved pathway involved in tissue development and regeneration that controls organ size through the regulation of cell proliferation and apoptosis. The core Hippo pathway is composed of a block of kinases, MST1/2 (Mammalian STE20-like protein kinase 1/2) and LATS1/2 (Large tumor suppressor 1/2), which inhibits nuclear translocation of YAP/TAZ (Yes-Associated Protein 1/Transcriptional co-activator with PDZ-binding motif) and its downstream association with the TEAD (TEA domain) family of transcription factors. This pathway was recently shown to be involved in tumorigenesis and metastasis in several cancers such as lung, breast, or colorectal cancers but is still poorly investigated in brain tumors. Gliomas are the most common and the most lethal primary brain tumors representing about 80% of malignant central nervous system neoplasms. Despite intensive clinical protocol, the prognosis for patients remains very poor due to systematic relapse and treatment failure. Growing evidence demonstrating the role of Hippo signaling in cancer biology and the lack of efficient treatments for malignant gliomas support the idea that this pathway could represent a potential target paving the way for alternative therapeutics. Based on recent advances in the Hippo pathway deciphering, the main goal of this review is to highlight the role of this pathway in gliomas by a state-of-the-art synthesis.
- Published
- 2021
- Full Text
- View/download PDF
28. Dual MGMT inactivation by promoter hypermethylation and loss of the long arm of chromosome 10 in glioblastoma.
- Author
-
Richard S, Tachon G, Milin S, Wager M, and Karayan-Tapon L
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Analysis of Variance, Antineoplastic Agents, Alkylating therapeutic use, Central Nervous System Neoplasms drug therapy, Central Nervous System Neoplasms enzymology, Central Nervous System Neoplasms mortality, Comparative Genomic Hybridization, CpG Islands genetics, DNA Methylation, DNA Modification Methylases genetics, DNA Repair Enzymes genetics, Female, Gene Silencing, Glioblastoma drug therapy, Glioblastoma enzymology, Glioblastoma mortality, High-Throughput Nucleotide Sequencing, Humans, Male, Middle Aged, Progression-Free Survival, Promoter Regions, Genetic, Retrospective Studies, Temozolomide therapeutic use, Time Factors, Tumor Suppressor Proteins genetics, Young Adult, Central Nervous System Neoplasms genetics, Chromosome Deletion, Chromosomes, Human, Pair 10 genetics, DNA Modification Methylases metabolism, DNA Repair Enzymes metabolism, Glioblastoma genetics, Tumor Suppressor Proteins metabolism
- Abstract
Background: Epigenetic inactivation of O6-methylguanine-methyltransferase (MGMT) gene by methylation of its promoter is predictive of Temozolomid (TMZ) response in glioblastoma (GBM). MGMT is located on chromosome 10q26 and the loss of chromosome 10q is observed in 70% of GBMs. In this study, we assessed the hypothesis that the dual inactivation of MGMT, by hypermethylation of MGMT promoter and by loss the long arm of chromosome 10 (10q), may confer greater sensitivity to TMZ., Methods: A total of 149 tumor samples from patients diagnosed with GBM based on the WHO 2016 classification were included in this retrospective study between November 2016 and December 2018. Methylation status of MGMT promoter was evaluated by pyrosequencing and status of chromosome 10q was assessed by array comparative genomic hybridization., Results: Glioblastoma patients with chromosome 10q loss associated with hypermethylation of MGMT promoter had significantly longer overall survival (OS) (P = .0024) and progression-free survival (PFS) (P = .031). Indeed, median OS of patients with dual inactivation of MGMT was 21.5 months compared to 12 months and 8.1 months for groups with single MGMT inactivation by hypermethylation and by 10q loss, respectively. The group with no MGMT inactivation had 9.5 months OS. Moreover, all long-term survivors with persistent response to TMZ treatment (OS ≥ 30 months) displayed dual inactivation of MGMT., Conclusions: Our data suggest that the molecular subgroup characterized by the dual inactivation of MGMT receives greater benefit from TMZ treatment. The results of our study may be of immediate clinical interest since chromosome 10q status and methylation of MGMT promoter are commonly determined in routine practice., (© 2020 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.)
- Published
- 2020
- Full Text
- View/download PDF
29. Detection of Colorectal Cancer and Advanced Adenoma by Liquid Biopsy (Decalib Study): The ddPCR Challenge.
- Author
-
Junca A, Tachon G, Evrard C, Villalva C, Frouin E, Karayan-Tapon L, and Tougeron D
- Abstract
Background: In most countries, participation in colorectal cancer (CRC) screening programs with the immunological fecal occult blood test (iFOBT) is low. Mutations of RAS and BRAF occur early in colorectal carcinogenesis and "liquid biopsy" allows detection of mutated circulating tumor DNA (ctDNA). This prospective study aims to evaluate the performance of RAS and BRAF-mutated ctDNA in detecting CRC and advanced adenomas (AA)., Methods: One hundred and thirty patients who underwent colonoscopy for suspicion of colorectal lesion were included and divided into four groups: 20 CRC, 39 AA, 31 non-advanced adenoma and/or hyperplastic polyp(s) (NAA) and 40 with no lesion. Mutated ctDNA was analyzed by droplet digital PCR., Results: ctDNA was detected in 45.0% of CRC, in 2.6% of AA and none of the NAA and "no-lesion" groups. All patients with stage II to IV mutated CRC had detectable ctDNA ( n = 8/8). Among the mutated AA, only one patient had detectable ctDNA (4.3%), maybe due to limited technical sensitivity or to a low rate of ctDNA or even the absence ctDNA in plasma. Specificity and sensitivity of KRAS- and BRAF-mutated ctDNA for the detection of all CRC and AA were 100% and 16.9%, respectively., Conclusions: ctDNA had high sensitivity in detection of advanced mutated CRC but was unable to sensitively detect AA. ctDNA analysis was easy to perform and readily accepted by the population but requires combination with other circulating biomarkers before replacing iFOBT.
- Published
- 2020
- Full Text
- View/download PDF
30. Targeted RNA-sequencing assays: a step forward compared to FISH and IHC techniques?
- Author
-
Tachon G, Cortes U, Richard S, Martin S, Milin S, Evrard C, Lamour C, and Karayan-Tapon L
- Subjects
- Adult, Aged, Aged, 80 and over, Anaplastic Lymphoma Kinase genetics, Biomarkers, Tumor, Biopsy, Carcinoma, Non-Small-Cell Lung genetics, Female, High-Throughput Nucleotide Sequencing, Humans, Immunohistochemistry, In Situ Hybridization, Fluorescence, Lung Neoplasms genetics, Male, Middle Aged, Oncogene Proteins, Fusion, Protein-Tyrosine Kinases genetics, Proto-Oncogene Proteins genetics, Sequence Analysis, RNA standards, Exome Sequencing, Sequence Analysis, RNA methods
- Abstract
Introduction: ALK and ROS1 rearrangements are molecular targets of several tyrosine kinase inhibitors. RNA-sequencing approaches are regarded as the new standard for fusion gene detection, representing an alternative to standard immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) techniques., Patients and Methods: We aimed to compare two recent amplicon-based RNA-sequencing techniques: FusionPlex
® Alk Ret Ros1 v2 Kit (Archer® ) with FHS-003Z-12-Human Lung Cancer Panel (Qiagen® ) and assessed the accuracy of the data for therapy management. Thirty-seven formalin-fixed paraffin-embedded non-small cell carcinoma (NSCC) lesions initially explored by IHC and FISH were selected for RNA-sequencing analysis., Results: Qiagen® and Archer® kits produced similar results and correctly identified 85.1% (23/27) and 81.5% (22/27) of IHC/FISH ALK- and ROS1-positive samples, respectively, and 100% (6/6) of the negative samples. With regard to the ambiguous IHC-positive/FISH-negative cases, RNA-sequencing confirmed 75% (3/4) of the FISH conclusion. Although not statistically significant, patients with common EML4-ALK variants presented shorter overall survival and progression-free survival compared with patients harboring rare variants., Conclusion: Our findings assessed the implementation of RNA-sequencing approaches to explore ALK and ROS1 rearrangements from formalin-fixed paraffin-embedded samples. We highlighted the similarities between Qiagen® and Archer® kits in terms of handling time, cost, and outcomes. We confirmed the feasibility of molecular testing in routine organization and its possible use not only as an alternative for standard IHC and FISH techniques, but as a supplementary technique helping to classify discrepant cases., (© 2019 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.)- Published
- 2019
- Full Text
- View/download PDF
31. Microsatellite Instability: Diagnosis, Heterogeneity, Discordance, and Clinical Impact in Colorectal Cancer.
- Author
-
Evrard C, Tachon G, Randrian V, Karayan-Tapon L, and Tougeron D
- Abstract
Tumor DNA mismatch repair (MMR) deficiency testing is important to the identification of Lynch syndrome and decision making regarding adjuvant chemotherapy in stage II colorectal cancer (CRC) and has become an indispensable test in metastatic tumors due to the high efficacy of immune checkpoint inhibitor (ICI) in deficient MMR (dMMR) tumors. CRCs greatly benefit from this testing as approximately 15% of them are dMMR but only 3% to 5% are at a metastatic stage. MMR status can be determined by two different methods, microsatellite instability (MSI) testing on tumor DNA, and immunohistochemistry of the MMR proteins on tumor tissue. Recent studies have reported a rate of 3% to 10% of discordance between these two tests. Moreover, some reports suggest possible intra- and inter-tumoral heterogeneity of MMR and MSI status. These issues are important to know and to clarify in order to define therapeutic strategy in CRC. This review aims to detail the standard techniques used for the determination of MMR and MSI status, along with their advantages and limits. We review the discordances that may arise between these two tests, tumor heterogeneity of MMR and MSI status, and possible explanations. We also discuss the strategies designed to distinguish sporadic versus germline dMMR/MSI CRC. Finally, we present new and accurate methods aimed at determining MMR/MSI status ., Competing Interests: Abbreviations:
- Published
- 2019
- Full Text
- View/download PDF
32. Transcriptional alterations in glioma result primarily from DNA methylation-independent mechanisms.
- Author
-
Court F, Le Boiteux E, Fogli A, Müller-Barthélémy M, Vaurs-Barrière C, Chautard E, Pereira B, Biau J, Kemeny JL, Khalil T, Karayan-Tapon L, Verrelle P, and Arnaud P
- Subjects
- Adult, Cell Line, Tumor, Chromatin genetics, CpG Islands genetics, Female, Gene Expression Regulation, Neoplastic genetics, Glioma pathology, Histones genetics, Humans, Isocitrate Dehydrogenase genetics, Jumonji Domain-Containing Histone Demethylases genetics, Male, Promoter Regions, Genetic, DNA Methylation genetics, Epigenesis, Genetic genetics, Glioma genetics, Transcription, Genetic
- Abstract
In cancer cells, aberrant DNA methylation is commonly associated with transcriptional alterations, including silencing of tumor suppressor genes. However, multiple epigenetic mechanisms, including polycomb repressive marks, contribute to gene deregulation in cancer. To dissect the relative contribution of DNA methylation-dependent and -independent mechanisms to transcriptional alterations at CpG island/promoter-associated genes in cancer, we studied 70 samples of adult glioma, a widespread type of brain tumor, classified according to their isocitrate dehydrogenase ( IDH1 ) mutation status. We found that most transcriptional alterations in tumor samples were DNA methylation-independent. Instead, altered histone H3 trimethylation at lysine 27 (H3K27me3) was the predominant molecular defect at deregulated genes. Our results also suggest that the presence of a bivalent chromatin signature at CpG island promoters in stem cells predisposes not only to hypermethylation, as widely documented, but more generally to all types of transcriptional alterations in transformed cells. In addition, the gene expression strength in healthy brain cells influences the choice between DNA methylation- and H3K27me3-associated silencing in glioma. Highly expressed genes were more likely to be repressed by H3K27me3 than by DNA methylation. Our findings support a model in which altered H3K27me3 dynamics, more specifically defects in the interplay between polycomb protein complexes and the brain-specific transcriptional machinery, is the main cause of transcriptional alteration in glioma cells. Our study provides the first comprehensive description of epigenetic changes in glioma and their relative contribution to transcriptional changes. It may be useful for the design of drugs targeting cancer-related epigenetic defects., (© 2019 Court et al.; Published by Cold Spring Harbor Laboratory Press.)
- Published
- 2019
- Full Text
- View/download PDF
33. Prognostic significance of MEOX2 in gliomas.
- Author
-
Tachon G, Masliantsev K, Rivet P, Petropoulos C, Godet J, Milin S, Wager M, Guichet PO, and Karayan-Tapon L
- Subjects
- Adult, Aged, Aged, 80 and over, Brain Neoplasms metabolism, Brain Neoplasms mortality, Female, Glioma metabolism, Glioma mortality, Humans, Male, Middle Aged, Prognosis, Young Adult, Biomarkers, Tumor analysis, Brain Neoplasms pathology, Glioma pathology, Homeodomain Proteins biosynthesis
- Abstract
Gliomas are the most common malignant primary tumors in the central nervous system and have variable predictive clinical courses. Glioblastoma, the most aggressive form of glioma, is a complex disease with unsatisfactory therapeutic solutions and a very poor prognosis. Some processes at stake in gliomagenesis have been discovered but little is known about the role of homeobox genes, even though they are highly expressed in gliomas, particularly in glioblastoma. Among them, the transcription factor Mesenchyme Homeobox 2 (MEOX2) had previously been associated with malignant progression and clinical prognosis in lung cancer and hepatocarcinoma but never studied in glioma. The aim of our study was to investigate the clinical significance of MEOX2 in gliomas. We assessed the expression of MEOX2 according to IDH1/2 molecular profile and patient survival among three different public datasets: The Cancer Genome Atlas (TCGA), The Chinese Glioma Genome Atlas (CGGA) and the US National Cancer Institute Repository for Molecular Brain Neoplasia Data (Rembrandt). We then evaluated the prognostic significance of MEOX2 protein expression on 112 glioma clinical samples including; 56 IDH1 wildtype glioblastomas, 7 IDH1 wild-type lower grade gliomas, 49 IDH1 mutated lower grade gliomas. Survival rates were estimated by the Kaplan-Meier method followed by uni/multivariate analyses. We demonstrated that MEOX2 was one of the transcription factors most closely associated with overall survival in glioma. Moreover, MEOX2 expression was associated with IDH1/2 wildtype molecular subtype and was significantly correlated with overall survival of all gliomas and, more interestingly, in lower grade glioma. To conclude, our results may be the first to provide insight into the clinical significance of MEOX2 in gliomas, which is a factor closely related to patient outcome. MEOX2 could constitute an interesting prognostic biomarker, especially for lower grade glioma.
- Published
- 2019
- Full Text
- View/download PDF
34. Histomolecular characterization of intracranial meningiomas developed in patients exposed to high-dose cyproterone acetate: an antiandrogen treatment.
- Author
-
Portet S, Naoufal R, Tachon G, Simonneau A, Chalant A, Naar A, Milin S, Bataille B, and Karayan-Tapon L
- Abstract
Background: Meningiomas are the most common primary intracranial tumors in adults. The relationship between meningiomas and exogenous sex hormones such as cyproterone acetate (CPA) is well documented, yet the underlying mechanisms remain unknown. Defining the histomolecular status of meningiomas developed on CPA would help us to better understand the oncogenesis of these tumors., Methods: We identified 30 patients operated for a meningioma after long-term high-dose CPA therapy and with a history of CPA discontinuation before establishing the indication for surgical intervention. We used array-comparative genomic hybridization (to characterize copy number changes in those 30 meningiomas and subsequently performed next-generation sequencing with the National Institute of Cancer (INCa) solid tumor panel, which is a targeted panel of clinically actionable genes. We also examined grade, type, and clinical features., Results: We identified AKT1 mutations or PIK3CA mutations in 33.3% of CPA meningiomas. AKT1 and PIK3CA mutations were mutually exclusive. Enrichment in oncogenic PIK3CA mutations in the CPA cohort was detected. CPA meningiomas showed chromosomal stability and were located mainly in the skull base. Ninety percent of CPA meningiomas were low-grade meningiomas and 63.4% were meningotheliomas. Half of our CPA cohort had microcystic components., Conclusion: Our study shows that low-grade meningothelial meningiomas of the skull base are predominant in CPA meningiomas. We identified PIK3CA/AKT1 pathway as a hypothetical actor in onco-pharmacological interaction between meningiomas and CPA. This signaling pathway could be an interesting target for precision medicine trials in meningioma patients who have been subjected to CPA. Our results could invite the scientific community to review the current classification of meningiomas and to evolve toward more specific histomolecular classification., (© The Author(s) 2019. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.)
- Published
- 2019
- Full Text
- View/download PDF
35. Pathological and Molecular Characteristics of Colorectal Cancer with Brain Metastases.
- Author
-
Roussille P, Tachon G, Villalva C, Milin S, Frouin E, Godet J, Berger A, Emambux S, Petropoulos C, Wager M, Karayan-Tapon L, and Tougeron D
- Abstract
Background: Colorectal cancers (CRC) with brain metastases (BM) are scarcely described. The main objective of this study was to determine the molecular profile of CRC with BM. Methods: We included 82 CRC patients with BM. KRAS , NRAS , BRAF and mismatch repair (MMR) status were investigated on primary tumors ( n = 82) and BM ( n = 38). ALK, ROS1, cMET, HER-2, PD-1, PD-L1, CD3 and CD8 status were evaluated by immunohistochemistry, and when recommended, by fluorescence in situ hybridization. Results: In primary tumors, KRAS , NRAS and BRAF mutations were observed in 56%, 6%, and 6% of cases, respectively. No ROS1 , ALK and cMET rearrangement was detected. Only one tumor presented HER-2 amplification. Molecular profiles were mostly concordant between BM and paired primary tumors, except for 9% of discordances for RAS mutation. CD3, CD8, PD-1 and PD-L1 expressions presented some discordance between primary tumors and BM. In multivariate analysis, multiple BM, lung metastases and PD-L1+ tumor were predictive of poor overall survival. Conclusions: CRCs with BM are associated with high frequency of RAS mutations and significant discordance for RAS mutational status between BM and paired primary tumors. Multiple BM, lung metastases and PD-L1+ have been identified as prognostic factors and can guide therapeutic decisions for CRC patients with BM., Competing Interests: The authors declare no conflict of interest.
- Published
- 2018
- Full Text
- View/download PDF
36. Cell Cycle Changes after Glioblastoma Stem Cell Irradiation: The Major Role of RAD51.
- Author
-
Tachon G, Cortes U, Guichet PO, Rivet P, Balbous A, Masliantsev K, Berger A, Boissonnade O, Wager M, and Karayan-Tapon L
- Subjects
- Cell Line, Tumor, DNA Repair, Gene Expression Regulation, Neoplastic, Glioblastoma metabolism, Glioblastoma pathology, Humans, Rad51 Recombinase metabolism, Radiation Tolerance genetics, Cell Cycle genetics, Cell Cycle radiation effects, Glioblastoma genetics, Neoplastic Stem Cells metabolism, Neoplastic Stem Cells radiation effects, Rad51 Recombinase genetics, Radiation, Ionizing
- Abstract
"Glioma Stem Cells" (GSCs) are known to play a role in glioblastoma (GBM) recurrence. Homologous recombination (HR) defects and cell cycle checkpoint abnormalities can contribute concurrently to the radioresistance of GSCs. DNA repair protein RAD51 homolog 1 (RAD51) is a crucial protein for HR and its inhibition has been shown to sensitize GSCs to irradiation. The aim of this study was to examine the consequences of ionizing radiation (IR) for cell cycle progression in GSCs. In addition, we intended to assess the potential effect of RAD51 inhibition on cell cycle progression. Five radiosensitive GSC lines and five GSC lines that were previously characterized as radioresistant were exposed to 4Gy IR, and cell cycle analysis was done by fluorescence-activated cell sorting (FACS) at 24, 48, 72, and 96 h with or without RAD51 inhibitor. Following 4Gy IR, all GSC lines presented a significant increase in G2 phase at 24 h, which was maintained over 72 h. In the presence of RAD51 inhibitor, radioresistant GSCs showed delayed G2 arrest post-irradiation for up to 48 h. This study demonstrates that all GSCs can promote G2 arrest in response to radiation-induced DNA damage. However, following RAD51 inhibition, the cell cycle checkpoint response differed. This study contributes to the characterization of the radioresistance mechanisms of GSCs, thereby supporting the rationale of targeting RAD51-dependent repair pathways in view of radiosensitizing GSCs.
- Published
- 2018
- Full Text
- View/download PDF
37. Functional invadopodia formed in glioblastoma stem cells are important regulators of tumor angiogenesis.
- Author
-
Petropoulos C, Guichet PO, Masliantsev K, Wager M, and Karayan-Tapon L
- Abstract
Glioblastoma (GBM) represents the most common and lethal brain tumor. High vascularization, necrosis and invasiveness are hallmarks of GBM aggressiveness with recent data suggesting the important role of glioblastoma stem cells (GSCs) in these processes. It is now well established that cancer cells employ specialized structures termed invadosomes to potentiate invasion. However, the role of these structures in GBM dissemination remains poorly investigated. In this study, we showed that GBM-isolated GSCs form invadopodia-like protrusions endowed with degradative action. Interestingly, their formation depends on extracellular matrix (ECM) sensing via the CD44 receptor. We also found that GSCs invasive migration occurring during tubes assembly is promoted through invadopodia-mediated-ECM remodeling and LIM kinases signaling. Moreover, our study demonstrates that GSCs are highly adaptable cells that are able not only to restore damaged endothelial-derived tubes but also to generate in cooperation with normal endothelial cells (ECs) intact vascular channels. Taken together, our data provide new insights in GBM microvasculature and suggest that GSCs targeting in combination with anti-VEGF therapy may block tumor progression., Competing Interests: CONFLICTS OF INTEREST The authors declare no potential conflicts of interest.
- Published
- 2018
- Full Text
- View/download PDF
38. Association between clinicopathological characteristics and RAS mutation in colorectal cancer.
- Author
-
Rimbert J, Tachon G, Junca A, Villalva C, Karayan-Tapon L, and Tougeron D
- Subjects
- Adult, Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Mutation, Prognosis, Retrospective Studies, Biomarkers, Tumor genetics, Colorectal Neoplasms genetics, Colorectal Neoplasms pathology, GTP Phosphohydrolases genetics, Membrane Proteins genetics, Proto-Oncogene Proteins B-raf genetics, Proto-Oncogene Proteins p21(ras) genetics
- Abstract
In colorectal cancer, KRAS (exons 2, 3, and 4) and NRAS (exons 2, 3, and 4) mutations are associated with resistance to antiepidermal growth factor receptor monoclonal antibodies, and BRAF mutation is a molecular marker of poor prognosis. KRAS exon 2 and BRAF-mutated colorectal cancers have well-known distinct clinicopathological characteristics. Comparison of tumors with different RAS status (exons 2, 3, and 4 of KRAS and NRAS) based on their clinicopathological characteristics has never been established. All colorectal cancer patients with RAS and BRAF testing from 2011 to 2015 were included in this observational retrospective study. Patient and tumor characteristics were collected and correlation with RAS and BRAF status was evaluated. A total of 1735 patients with colorectal cancer were included. RAS-mutated colorectal cancers (n=1002), compared with RAS wild-type colorectal cancers (n=733), were significantly associated with male gender, classical adenocarcinoma subtype, well/moderately differentiated tumors, and microsatellite stable phenotype. KRAS codon 13-mutated colorectal cancers (n=171), compared with RAS wild-type colorectal cancers, more frequently presented classical adenocarcinoma subtype and microsatellite stable phenotype. In comparison with other RAS mutations, KRAS exon 3-mutated colorectal cancers (n=23) were associated with mucinous/rare histological subtypes and, most likely to located in the rectum. KRAS exon 4-mutated colorectal cancers (n=33) were more frequently associated with mucinous/rare histological subtypes. There was no significant association between NRAS mutation (n=37) and clinicopathological features. Colorectal cancers are associated with different clinicopathological features according to the type of RAS mutation. Consequently, these particular characteristics must be considered when assessing the prognostic value of RAS status in colorectal cancer.
- Published
- 2018
- Full Text
- View/download PDF
39. Impact of STAT3 phosphorylation in glioblastoma stem cells radiosensitization and patient outcome.
- Author
-
Masliantsev K, Pinel B, Balbous A, Guichet PO, Tachon G, Milin S, Godet J, Duchesne M, Berger A, Petropoulos C, Wager M, and Karayan-Tapon L
- Abstract
Glioblastoma (GBM) represents the most common and lethal primary malignant brain tumor. The standard treatment for glioblastoma patients involves surgical resection with concomitant radio and chemotherapy. Despite today's clinical protocol, the prognosis for patients remains very poor with a median survival of 15 months. Tumor resistance and recurrence is strongly correlated with a subpopulation of highly radioresistant and invasive cells termed Glioblastoma Stem Cells (GSCs). The transcription factor STAT3 has been found to be constitutively activated in different tumors including GBM and enhanced tumor radioresistance. In this study, we assessed radiosensitization of GSC lines isolated from patients by inhibition of STAT3 activation using Stattic or WP1066. We showed that inhibitor treatment before cell irradiation decreased the surviving fraction of GSCs suggesting that STAT3 inhibition could potentiate radiation effects. Finally, we investigated STAT3 activation status on 61 GBM clinical samples and found a preferential phosphorylation of STAT3 on Serine727 (pS727). Moreover, we found that pS727 was associated with a significant lower overall patient survival and progression-free survival but not pY705. Taken together, our results suggest that pS727-STAT3 could be a potential prognostic marker and could constitute a therapeutic target to sensitize highly radioresistant GSCs., Competing Interests: CONFLICTS OF INTEREST The authors have no conflicts to disclose.
- Published
- 2017
- Full Text
- View/download PDF
40. Analysis of factors influencing molecular testing at diagnostic of colorectal cancer.
- Author
-
Thiebault Q, Defossez G, Karayan-Tapon L, Ingrand P, Silvain C, and Tougeron D
- Subjects
- Aged, Aged, 80 and over, Biomarkers, Tumor, Colorectal Neoplasms genetics, Factor Analysis, Statistical, Female, Humans, Male, Microsatellite Instability, Middle Aged, Neoplasm Grading, Neoplasm Staging, Odds Ratio, Proto-Oncogene Proteins B-raf genetics, Proto-Oncogene Proteins p21(ras) genetics, Colorectal Neoplasms diagnosis, Molecular Diagnostic Techniques methods, Molecular Diagnostic Techniques standards
- Abstract
Background: The aim of the study was to evaluate the current rate of molecular testing prescription (KRAS codons 12/13, BRAF and microsatellite instability (MSI)) in newly diagnosed colorectal cancer (CRC) patients and to determine which factors influence testing., Methods: All incident CRC cases in 2010 were identified in the Poitou-Charentes General Cancer Registry. The exhaustive molecular testing performed was accessed in the French molecular genetics platform. Factors influencing prescription were analyzed using logistic regression., Results: Among the 1269 CRCs included in the study, KRAS, BRAF and MSI testing accounted for 35.1%, 10.5% and 10.9%, respectively. KRAS testing was carried out in 65.5% of metastatic CRCs, and 26.1% of non-metastatic CRCs. Among metastatic CRCs, age (<60 years), site of primary tumour (left colon) and geographical area of treatment were factors related to KRAS testing. BRAF testing was contemporary to KRAS testing for 92.5% of patients. Factors related to MSI testing were age (<60 years), TNM stage (stage IV) and geographical area of treatment. Among CRC patients under 60 years old, only 37.5% had MSI testing., Conclusion: These results underscore the need to reduce disparities in CRC molecular testing and highlight the limited application of the French guidelines, especially concerning MSI testing.
- Published
- 2017
- Full Text
- View/download PDF
41. Crizotinib targets in glioblastoma stem cells.
- Author
-
Junca A, Villalva C, Tachon G, Rivet P, Cortes U, Guilloteau K, Balbous A, Godet J, Wager M, and Karayan-Tapon L
- Subjects
- Aged, Anaplastic Lymphoma Kinase, Cell Line, Tumor, Central Nervous System Neoplasms genetics, Central Nervous System Neoplasms metabolism, Crizotinib, DNA Mutational Analysis, Female, Glioblastoma genetics, Glioblastoma metabolism, Humans, Male, Middle Aged, Molecular Targeted Therapy, Neoplastic Stem Cells metabolism, Pyrazoles metabolism, Pyridines metabolism, Central Nervous System Neoplasms drug therapy, Glioblastoma drug therapy, Protein Kinase Inhibitors therapeutic use, Protein-Tyrosine Kinases genetics, Protein-Tyrosine Kinases metabolism, Proto-Oncogene Proteins genetics, Proto-Oncogene Proteins metabolism, Proto-Oncogene Proteins c-met genetics, Proto-Oncogene Proteins c-met metabolism, Pyrazoles therapeutic use, Pyridines therapeutic use, Receptor Protein-Tyrosine Kinases genetics, Receptor Protein-Tyrosine Kinases metabolism
- Abstract
Glioblastoma stem cells (GSCs) are believed to be involved in the mechanisms of tumor resistance, therapeutic failures, and recurrences after conventional glioblastoma therapy. Therefore, elimination of GSCs might be a prerequisite for the development of successful therapeutic strategies. ALK, ROS1, and MET are targeted by Crizotinib, a tyrosine kinase inhibitor which has been approved for treatment of ALK-rearranged non-small-cell lung cancer. In this study we investigated ALK, ROS1, and MET status in nine glioblastoma stem cell lines and tumors from which they arise. Fluorescent in situ hybridization (FISH), Sanger's direct sequencing, and immunohistochemistry were used to screen genomic rearrangements (or amplifications), genomic mutations, and protein expression, respectively. The immunohistochemical and FISH studies revealed no significant dysregulation of ROS1 in GSCs and associated tumors. Neither amplification nor polysomy of ALK was observed in GSC, but weak overexpression was detected by IHC in three of nine GSCs. Similarly, no MET amplification was found by FISH but three GSCs presented significant immunohistochemical staining. No ALK or MET mutation was found by Sanger's direct sequencing. In this study, we show no molecular rearrangement of ALK, ROS1, and MET that would lead us not to propose, as a valid strategy, the use of crizotinib to eradicate GSCs. However, MET was overexpressed in all GSCs with mesenchymal subtype and three GSCs presented an overexpression of ALK. Therefore, our study corroborates the idea that MET and ALK may assume a role in the tumorigenicity of GSC., (© 2017 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.)
- Published
- 2017
- Full Text
- View/download PDF
42. SETMAR isoforms in glioblastoma: A matter of protein stability.
- Author
-
Dussaussois-Montagne A, Jaillet J, Babin L, Verrelle P, Karayan-Tapon L, Renault S, Rousselot-Denis C, Zemmoura I, and Augé-Gouillou C
- Subjects
- Alternative Splicing, Animals, Brain Neoplasms genetics, Brain Neoplasms pathology, CHO Cells, Cell Line, Tumor, Cricetulus, Enzyme Stability, Gene Expression Regulation, Enzymologic, Gene Expression Regulation, Neoplastic, Glioblastoma genetics, Glioblastoma pathology, Histone-Lysine N-Methyltransferase genetics, Humans, Neoplastic Stem Cells pathology, Protein Isoforms, RNA, Messenger genetics, RNA, Messenger metabolism, Time Factors, Transfection, Brain Neoplasms enzymology, Glioblastoma enzymology, Histone-Lysine N-Methyltransferase metabolism, Neoplastic Stem Cells enzymology
- Abstract
Glioblastomas (GBMs) are the most frequent and the most aggressive brain tumors, known for their chemo- and radio-resistance, making them often incurable. We also know that SETMAR is a protein involved in chromatin dynamics and genome plasticity, of which overexpression confers chemo- and radio-resistance to some tumors. The relationships between SETMAR and GBM have never been explored. To fill this gap, we define the SETMAR status of 44 resected tumors and of GBM derived cells, at both the mRNA and the protein levels. We identify a new, small SETMAR protein (so called SETMAR-1200), enriched in GBMs and GBM stem cells as compared to the regular enzyme (SETMAR-2100). We show that SETMAR-1200 is able to increase DNA repair by non-homologous end-joining, albeit with a lower efficiency than the regular SETMAR protein. Interestingly, the regular/small ratio of SETMAR in GBM cells changes depending on cell type, providing evidence that SETMAR expression is regulated by alternative splicing. We also demonstrate that SETMAR expression can be regulated by the use of an alternative ATG. In conclusion, various SETMAR proteins can be synthesized in human GBM that may each have specific biophysical and/or biochemical properties and characteristics. Among them, the small SETMAR may play a role in GBMs biogenesis. On this basis, we would like to consider SETMAR-1200 as a new potential therapeutic target to investigate, in addition to the regular SETMAR protein already considered by others.
- Published
- 2017
- Full Text
- View/download PDF
43. High Intra- and Inter-Tumoral Heterogeneity of RAS Mutations in Colorectal Cancer.
- Author
-
Jeantet M, Tougeron D, Tachon G, Cortes U, Archambaut C, Fromont G, and Karayan-Tapon L
- Subjects
- Adult, Aged, Antibodies, Monoclonal administration & dosage, Cetuximab administration & dosage, Colorectal Neoplasms genetics, Colorectal Neoplasms pathology, Drug Resistance, Neoplasm genetics, ErbB Receptors antagonists & inhibitors, Female, Genetic Heterogeneity, Humans, Male, Middle Aged, Mutation, Neoplasm Metastasis, Colorectal Neoplasms drug therapy, GTP Phosphohydrolases genetics, Membrane Proteins genetics, Proto-Oncogene Proteins B-raf genetics, Proto-Oncogene Proteins p21(ras) genetics
- Abstract
Approximately 30% of patients with wild type RAS metastatic colorectal cancer are non-responders to anti-epidermal growth factor receptor monoclonal antibodies (anti-EGFR mAbs), possibly due to undetected tumoral subclones harboring RAS mutations. The aim of this study was to analyze the distribution of RAS mutations in different areas of the primary tumor, metastatic lymph nodes and distant metastasis. A retrospective cohort of 18 patients with a colorectal cancer (CRC) was included in the study. Multiregion analysis was performed in 60 spatially separated tumor areas according to the pathological tumor node metastasis (pTNM) staging and KRAS , NRAS and BRAF mutations were tested using pyrosequencing. In primary tumors, intra-tumoral heterogeneity for RAS mutation was found in 33% of cases. Inter-tumoral heterogeneity for RAS mutation between primary tumors and metastatic lymph nodes or distant metastasis was found in 36% of cases. Moreover, 28% of tumors had multiple RAS mutated subclones in the same tumor. A high proportion of CRCs presented intra- and/or inter-tumoral heterogeneity, which has relevant clinical implications for anti-EGFR mAbs prescription. These results suggest the need for multiple RAS testing in different parts of the same tumor and/or more sensitive techniques., Competing Interests: The authors declare no conflict of interest. The founding sponsors had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, and in the decision to publish the results.
- Published
- 2016
- Full Text
- View/download PDF
44. Validation of the high-performance of pyrosequencing for clinical MGMT testing on a cohort of glioblastoma patients from a prospective dedicated multicentric trial.
- Author
-
Quillien V, Lavenu A, Ducray F, Joly MO, Chinot O, Fina F, Sanson M, Carpentier C, Karayan-Tapon L, Rivet P, Entz-Werle N, Legrain M, Zalcman EL, Levallet G, Escande F, Ramirez C, Chiforeanu D, Vauleon E, and Figarella-Branger D
- Subjects
- Adult, Aged, DNA Methylation, Dacarbazine analogs & derivatives, Dacarbazine therapeutic use, Disease-Free Survival, Female, Humans, Male, Middle Aged, Promoter Regions, Genetic, Prospective Studies, Reproducibility of Results, Temozolomide, Young Adult, Brain Neoplasms genetics, DNA Modification Methylases genetics, DNA Repair Enzymes genetics, Glioblastoma genetics, Sequence Analysis, DNA, Tumor Suppressor Proteins genetics
- Abstract
Background: The goal of this prospective multicentric trial was to validate a technique that allowed for MGMT promoter methylation analysis in routine clinical practice., Methods: The MGMT status of 139 glioblastoma patients, whom had received standard first line treatment, was determined using pyrosequencing (PSQ) and a semi-quantitative Methylation-specific PCR (sqMS-PCR) method, using both frozen and formalin-fixed paraffin-embedded FFPE samples. Eight participating centers locally performed the analysis, including external quality controls., Results: There was a strong correlation between results from FFPE and frozen samples. With cut-offs of 12% and 13%, 98% and 91% of samples were identically classified with PSQ and sqMS-PCR respectively. In 12% of cases frozen samples were excluded because they had a low percentage of tumor cells. In 5-6% of cases the analysis was not feasible on FFPE samples. The optimized risk cut-offs were higher in both techniques when using FFPE samples, in comparison to frozen samples. For sqMS-PCR, we validated a cut-off between 13-15% to dichotomize patients. For PSQ, patients with a low level of methylation (<= 8%) had a median progression-free survival under 9 months, as compared with more than 15.5 months for those with a level above 12%. For intermediate values (9-12%), more discordant results between FFPE and frozen samples were observed and there was not a clear benefit of temozolomide treatment, which indicated a "grey zone"., Conclusions: MGMT status can reliably be investigated in local laboratories. PSQ is the ideal choice as proven by strong interlaboratory reproducibility, along with threshold agreements across independent studies., Competing Interests: There is no conflicts of interest for the authors and acknowledged contributors.
- Published
- 2016
- Full Text
- View/download PDF
45. A radiosensitizing effect of RAD51 inhibition in glioblastoma stem-like cells.
- Author
-
Balbous A, Cortes U, Guilloteau K, Rivet P, Pinel B, Duchesne M, Godet J, Boissonnade O, Wager M, Bensadoun RJ, Chomel JC, and Karayan-Tapon L
- Subjects
- Blotting, Western, Cell Line, Tumor, Comet Assay, DNA Damage radiation effects, Flow Cytometry, Humans, Immunohistochemistry, Neoplastic Stem Cells radiation effects, Tissue Array Analysis, Glioblastoma metabolism, Neoplastic Stem Cells metabolism, Rad51 Recombinase metabolism, Radiation Tolerance physiology
- Abstract
Background: Radioresistant glioblastoma stem cells (GSCs) contribute to tumor recurrence and identification of the molecular targets involved in radioresistance mechanisms is likely to enhance therapeutic efficacy. This study analyzed the DNA damage response following ionizing radiation (IR) in 10 GSC lines derived from patients., Methods: DNA damage was quantified by Comet assay and DNA repair effectors were assessed by Low Density Array. The effect of RAD51 inhibitor, RI-1, was evaluated by comet and annexin V assays., Results: While all GSC lines displayed efficient DNA repair machinery following ionizing radiation, our results demonstrated heterogeneous responses within two distinct groups showing different intrinsic radioresistance, up to 4Gy for group 1 and up to 8Gy for group 2. Radioresistant cell group 2 (comprising 5 out of 10 GSCs) showed significantly higher RAD51 expression after IR. In these cells, inhibition of RAD51 prevented DNA repair up to 180 min after IR and induced apoptosis. In addition, RAD51 protein expression in glioblastoma seems to be associated with poor progression-free survival., Conclusion: These results underscore the importance of RAD51 in radioresistance of GSCs. RAD51 inhibition could be a therapeutic strategy helping to treat a significant number of glioblastoma, in combination with radiotherapy.
- Published
- 2016
- Full Text
- View/download PDF
46. The tumoral A genotype of the MGMT rs34180180 single-nucleotide polymorphism in aggressive gliomas is associated with shorter patients' survival.
- Author
-
Fogli A, Chautard E, Vaurs-Barrière C, Pereira B, Müller-Barthélémy M, Court F, Biau J, Pinto AA, Kémény JL, Khalil T, Karayan-Tapon L, Verrelle P, Costa BM, and Arnaud P
- Subjects
- Adult, Brain Neoplasms mortality, Brain Neoplasms pathology, DNA Methylation genetics, Female, Genotype, Glioma mortality, Glioma pathology, Humans, Kaplan-Meier Estimate, Male, Polymerase Chain Reaction, Polymorphism, Restriction Fragment Length, Prognosis, Promoter Regions, Genetic genetics, Proportional Hazards Models, Retrospective Studies, Brain Neoplasms genetics, DNA Modification Methylases genetics, DNA Repair Enzymes genetics, Glioma genetics, Polymorphism, Single Nucleotide, Tumor Suppressor Proteins genetics
- Abstract
Malignant gliomas are the most common primary brain tumors. Grade III and IV gliomas harboring wild-type IDH1/2 are the most aggressive. In addition to surgery and radiotherapy, concomitant and adjuvant chemotherapy with temozolomide (TMZ) significantly improves overall survival (OS). The methylation status of the O(6)-methylguanine-DNA methyltransferase (MGMT) promoter is predictive of TMZ response and a prognostic marker of cancer outcome. However, the promoter regions the methylation of which correlates best with survival in aggressive glioma and whether the promoter methylation status predictive value could be refined or improved by other MGMT-associated molecular markers are not precisely known. In a cohort of 87 malignant gliomas treated with radiotherapy and TMZ-based chemotherapy, we retrospectively determined the MGMT promoter methylation status, genotyped single nucleotide polymorphisms (SNPs) in the promoter region and quantified MGMT mRNA expression level. Each of these variables was correlated with each other and with the patients' OS. We found that methylation of the CpG sites within MGMT exon 1 best correlated with OS and MGMT expression levels, and confirmed MGMT methylation as a stronger independent prognostic factor compared to MGMT transcription levels. Our main finding is that the presence of only the A allele at the rs34180180 SNP in the tumor was significantly associated with shorter OS, independently of the MGMT methylation status. In conclusion, in the clinic, rs34180180 SNP genotyping could improve the prognostic value of the MGMT promoter methylation assay in patients with aggressive glioma treated with TMZ., (© The Author 2015. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.)
- Published
- 2016
- Full Text
- View/download PDF
47. Efficacy of Adjuvant Chemotherapy in Colon Cancer With Microsatellite Instability: A Large Multicenter AGEO Study.
- Author
-
Tougeron D, Mouillet G, Trouilloud I, Lecomte T, Coriat R, Aparicio T, Des Guetz G, Lécaille C, Artru P, Sickersen G, Cauchin E, Sefrioui D, Boussaha T, Ferru A, Matysiak-Budnik T, Silvain C, Karayan-Tapon L, Pagès JC, Vernerey D, Bonnetain F, Michel P, Taïeb J, and Zaanan A
- Subjects
- Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Chemotherapy, Adjuvant, Colonic Neoplasms pathology, Colonic Neoplasms surgery, Female, Germ-Line Mutation, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Neoplasm Staging, Organoplatinum Compounds administration & dosage, Oxaliplatin, Pyrimidines administration & dosage, Retrospective Studies, Treatment Outcome, Antineoplastic Agents therapeutic use, Brain Neoplasms, Colonic Neoplasms drug therapy, Colonic Neoplasms genetics, Colorectal Neoplasms, Microsatellite Instability, Neoplastic Syndromes, Hereditary, Pyrimidines therapeutic use
- Abstract
Background: Deficient mismatch repair (dMMR) colon cancer (CC) is reportedly resistant to 5-fluorouracil (5FU) adjuvant chemotherapy while preliminary data suggest chemosensitivity to oxaliplatin. We assessed the efficacy of fluoropyrimidine with and without oxaliplatin in a large cohort of dMMR CC patients., Methods: This retrospective multicenter study included all consecutive patients who underwent curative surgical resection for stage II or III dMMR CC between 2000 and 2011. Prognostic factors were analyzed using Cox models, and hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated. All statistical tests were two-sided., Results: A total of 433 dMMR CC patients were included (56.8% stage II, 43.2% stage III). Mean follow-up was 47.0 months. The patients received surgery alone (n = 263) or surgery plus adjuvant chemotherapy consisting of fluoropyrimidine with (n = 119) or without (n = 51) oxaliplatin. Adjuvant chemotherapy was administered to 16.7% of stage II and 69.0% of stage III CC patients. As compared with surgery alone, adjuvant oxaliplatin-based chemotherapy improved disease-free survival (DFS) in multivariable analysis (HR = 0.35, 95% CI = 0.19 to 0.65, P < .001), contrary to adjuvant fluoropyrimidine alone (HR = 0.73, 95% CI = 0.36 to 1.49, P = .38). In the subgroup analysis, the DFS benefit of oxaliplatin-based chemotherapy was statistically significant in multivariable analysis only in stage III (HR = 0.41, 95% CI = 0.19 to 0.87, P = .02)., Conclusion: This study supports the use of adjuvant chemotherapy with fluoropyrimidine plus oxaliplatin in stage III dMMR CC., (© The Author 2016. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2016
- Full Text
- View/download PDF
48. IL22/IL-22R pathway induces cell survival in human glioblastoma cells.
- Author
-
Akil H, Abbaci A, Lalloué F, Bessette B, Costes LM, Domballe L, Charreau S, Guilloteau K, Karayan-Tapon L, Bernard FX, Morel F, Jauberteau MO, and Lecron JC
- Subjects
- Cell Line, Tumor, Cell Proliferation, Cell Survival genetics, Gene Expression, Glioblastoma genetics, Humans, Interleukin-10 Receptor beta Subunit genetics, Interleukin-10 Receptor beta Subunit metabolism, Interleukins genetics, MAP Kinase Signaling System, Neoplastic Stem Cells, Phosphorylation, Proto-Oncogene Proteins c-akt metabolism, Receptors, Interleukin genetics, STAT3 Transcription Factor metabolism, Interleukin-22, Glioblastoma metabolism, Interleukins metabolism, Receptors, Interleukin metabolism, Signal Transduction
- Abstract
Interleukin-22 (IL-22) is a member of the IL-10 cytokine family that binds to a heterodimeric receptor consisting of IL-22 receptor 1 (IL-22R1) and IL-10R2. IL-22R expression was initially characterized on epithelial cells, and plays an essential role in a number of inflammatory diseases. Recently, a functional receptor was detected on cancer cells such as hepatocarcinoma and lung carcinoma, but its presence was not reported in glioblastoma (GBM). Two GBM cell lines and 10 primary cell lines established from patients undergoing surgery for malignant GBM were used to investigate the expression of IL-22 and IL-22R by using quantitative RT-PCR, western blotting and confocal microscopy studies. The role of IL-22 in proliferation and survival of GBM cell lines was investigated in vitro by BrdU and ELISA cell death assays. We report herein that the two subunits of the IL-22R complex are expressed on human GBM cells. Their activation, depending on exogenous IL-22, induced antiapoptotic effect and cell proliferation. IL-22 treatment of GBM cells resulted in increased levels of phosphorylated Akt, STAT3 signaling protein and its downstream antiapoptotic protein Bcl-xL and decreased level of phosphorylated ERK1/2. In addition, IL-22R subunits were expressed in all the 10 tested primary cell lines established from GBM tumors. Our results showed that IL-22R is expressed on GBM established and primary cell lines. Depending on STAT3, ERK1/2 and PI3K/Akt pathways, IL-22 induced GBM cell survival. These data are consistent with a potential role of IL-22R in tumorigenesis of GBM. Since endogenous IL-22 was not detected in all studied GBM cells, we hypothesize that IL-22R could be activated by immune microenvironmental IL-22 producing cells.
- Published
- 2015
- Full Text
- View/download PDF
49. DGKI methylation status modulates the prognostic value of MGMT in glioblastoma patients treated with combined radio-chemotherapy with temozolomide.
- Author
-
Etcheverry A, Aubry M, Idbaih A, Vauleon E, Marie Y, Menei P, Boniface R, Figarella-Branger D, Karayan-Tapon L, Quillien V, Sanson M, de Tayrac M, Delattre JY, and Mosser J
- Subjects
- Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Alkylating therapeutic use, Chemoradiotherapy, Cohort Studies, Dacarbazine analogs & derivatives, Dacarbazine therapeutic use, Disease-Free Survival, Female, Glioblastoma drug therapy, Glioblastoma genetics, Glioblastoma radiotherapy, Humans, Isocitrate Dehydrogenase genetics, Male, Middle Aged, Nomograms, Prognosis, Proportional Hazards Models, Retrospective Studies, Temozolomide, Young Adult, DNA Methylation genetics, DNA Modification Methylases genetics, DNA Repair Enzymes genetics, Diacylglycerol Kinase genetics, Glioblastoma mortality, Promoter Regions, Genetic genetics, Tumor Suppressor Proteins genetics
- Abstract
Background: Consistently reported prognostic factors for glioblastoma (GBM) are age, extent of surgery, performance status, IDH1 mutational status, and MGMT promoter methylation status. We aimed to integrate biological and clinical prognostic factors into a nomogram intended to predict the survival time of an individual GBM patient treated with a standard regimen. In a previous study we showed that the methylation status of the DGKI promoter identified patients with MGMT-methylated tumors that responded poorly to the standard regimen. We further evaluated the potential prognostic value of DGKI methylation status., Methods: 399 patients with newly diagnosed GBM and treated with a standard regimen were retrospectively included in this study. Survival modelling was performed on two patient populations: intention-to-treat population of all included patients (population 1) and MGMT-methylated patients (population 2). Cox proportional hazard models were fitted to identify the main prognostic factors. A nomogram was developed for population 1. The prognostic value of DGKI promoter methylation status was evaluated on population 1 and population 2., Results: The nomogram-based stratification of the cohort identified two risk groups (high/low) with significantly different median survival. We validated the prognostic value of DGKI methylation status for MGMT-methylated patients. We also demonstrated that the DGKI methylation status identified 22% of poorly responding patients in the low-risk group defined by the nomogram., Conclusions: Our results improve the conventional MGMT stratification of GBM patients receiving standard treatment. These results could help the interpretation of published or ongoing clinical trial outcomes and refine patient recruitment in the future.
- Published
- 2014
- Full Text
- View/download PDF
50. Selective release of a cyclopamine glucuronide prodrug toward stem-like cancer cell inhibition in glioblastoma.
- Author
-
Balbous A, Renoux B, Cortes U, Milin S, Guilloteau K, Legigan T, Rivet P, Boissonnade O, Martin S, Tripiana C, Wager M, Bensadoun RJ, Papot S, and Karayan-Tapon L
- Subjects
- Animals, Brain Neoplasms drug therapy, Cell Line, Tumor, Cell Proliferation, Cell Survival, Drug Design, Drug Screening Assays, Antitumor, Female, Hedgehog Proteins antagonists & inhibitors, Humans, Inhibitory Concentration 50, Methylcellulose chemistry, Mice, Mice, Nude, Neoplasm Transplantation, Glioblastoma drug therapy, Glucuronides chemistry, Neoplastic Stem Cells cytology, Prodrugs chemistry, Veratrum Alkaloids chemistry
- Abstract
Recent data suggest that inhibition of the Hedgehog pathway could be a therapeutic target for glioblastoma. Alkaloid cyclopamine inhibits Hedgehog signaling, depleting stem-like cancer cells derived from glioblastoma. However, this compound is toxic for somatic stem cells, preventing its use for clinical applications. In this study, we tested a derivatization product of cyclopamine in the form of cyclopamine glucuronide prodrug (CGP-2). This compound was used in vitro and in vivo toward glioblastoma-initiating cells (GIC). Results obtained in vitro indicate that CGP-2 is active only in the presence of β-glucuronidase, an enzyme detected in high levels in necrotic areas of glioblastomas. CGP-2 decreased proliferation and inhibited the self-renewal of all GIC lines tested. Hedgehog pathway blockade by 10 μmol/L of CGP-2 induced a 99% inhibition of clonogenicity on GICs, similar to cyclopamine treatment. Combination of CGP-2 with radiation decreased clonogenic survival in all GIC lines compared with CGP-2 alone. In a subcutaneous glioblastoma xenograft model, a two-week CGP-2 treatment prevented tumor growth with 75% inhibition at 8 weeks, and this inhibition was still significant after 14 weeks. Unlike cyclopamine, CGP-2 had no detectable toxic effects in intestinal crypts. Our study suggests that inhibition of the Hedgehog pathway with CGP-2 is more effective than conventional temozolomide adjuvant, with much lower concentrations, and seems to be an effective therapeutic strategy for targeting GICs., (©2014 American Association for Cancer Research.)
- Published
- 2014
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.